1. Executive Summary 2. Research Methodology 3. Introduction 4. Global Biologics Market 4.1 OVERVIEW 4.1.1 Classification of Biologics 4.2 GLOBAL BIOLOGICS MARKET ANALYSIS 1.1.1 Market Sizing (Actual & Forecasted) 5. Global Biosimilars Market 5.1 OVERVIEW 5.2 MARKET ANALYSIS 5.2.1 Market Sizing (Actual & Forecasted) 2.1.1 Market Share by Region (Actual & Forecasted) 3.1.1 Market Share by Application (Actual & Forecasted) 4.1.1 Market by Product Pipeline 6. Global Biosimilars Market Segmentation 6.1 ERYTHROPOIETIN (EPO) 6.1.1 Overview 6.1.2 Market Analysis 6.2 INSULIN 6.2.1 Overview 6.2.2 Market Analysis 6.3 HUMAN GROWTH HORMONE (HGH) 6.3.1 Overview 6.3.2 Market Analysis 6.4 GRANULOCYTE- COLONY STIMULATING FACTOR (G-CSF) 6.4.1 Overview 6.4.2 6.4.2 Market Analysis 6.4.2 6.4.2 Market Analysis 6.5 MONOCLONAL ANTIBODY (MAB) 6.5.1 Overview 6.5.2 Market Analysis 6.6 INTERFERON (IFN) 6.6.1 6.6.1 Overview 6.6.2 Market Analysis 7. Global Biosimilars Market Analysis – Developed & Emerging Nations 7.1 DEVELOPED MARKET 7.1.1Europe 7.1.2 The US 7.2 EMERGING MARKET 7.2.1 China 7.2.2India 8. Global Biosimilars – Pricing Analysis 9. Global Biosimilar Industry – SWOT Analysis 10. Global Biosimilars Market Attractiveness Index 11. Global Biosimilars Market Dynamics 11.1 INDUSTRY TRENDS & DEVELOPMENTS 11.1.1 New Biosimilars Dominated by Large Globals 11.1.2 11.1.2 Biosimilar Interchangeability Guidance by FDA 11.1.3 11.1.3 Focus on Pharmerging Markets 11.2 GROWTH DRIVERS 11.2.1 11.2.1 Biological Patent Expiries 11.2.2 11.2.2 Cost saving 11.2.3 11.2.3 Increased use for Treatment of Chronic Diseases 11.3 CHALLENGES 11.3.1 11.3.1 High Cost of Development 11.3.2 11.3.2 Regulatory Uncertainty 11.3.3 11.3.3 Lower Adoption Rate of Biosimilars 11.3.4 11.3.4 Manufacturer Skills Gap 12. Competitive Landscape 12.1 MARKET SHARE BY COMPETITORS 12.2 MARKET SHARE BY DRUGS 13. Company Profiles 13.1 SANDOZ 13.2 HOSPIRA 13.3 TEVA 13.4 CELLTRION 13.5 BIOCAD 13.6 DONG-A PHARMACEUTICAL CO., LTD 13.7 STADA

Figure 1: Research Methodology – Rockville Research Figure 2: Classification of Biologics Figure 3: Global Biologics Market Size and Growth, 2007-16E (US$ Billions, %) Figure 4: Global Biologics Market Size by Value Forecasted, 2017E-22E (US$ Billions) Figure 5: Global Biosimilars Market Size by Value, 2010-16E (US$ Billions) Figure 6: Global Biosimilars Market Size by Value Foreacsted, 2017E-22E (US$ Billions) Figure 7: Global Biosimilars Market Share by Region (2015) Figure 8: Global Biosimilars Market Share by Region Forecasted (2020E) Figure 9: Global Biosimilars Market Share by Region (2015) Figure 10: Global Biosimilars Market Share by Region Forecasted (2020E) Figure 11: Global Biosimilar Pipeline by Therapy Area (2015) Figure 12: Global Biosimilar Product Pipeline by Phase, 2015 Figure 13: Global Continent-wise Biosimilar Candidates in Research Pipeline (as of Sept’16) Table 1: Biosimilar - EPOs Approved for Marketing Globally Table 2: Biological EPOs Patent Expiry Status Table 3: Biosimilar EPOs in Pipeline Figure 14: Global Erythropoietin (EPOs) Biosimilars Market Size by Value, 2014-2020E (US$ Millions) Table 4: Global Biosimilars - Insulins Pipeline Figure 15: Current and Projected Cases of Diabetes by Region, 2013 & 2035F Table 5: Global - Biosimilar Insulin Approved for Marketing Figure 16: Global - Insulin Biosimilars Market Size by Value, 2014-2020E (US$ Millions) Table 6: Global - Patent Expiry Status of Insulin Table 7: Global - Biosimilar HGH Approved for Marketing Table 8: Global - Biosimilar HGH in Pipeline Figure 17: Global - HGH Biosimilars Market Size by Value, 2014-2020E (US$ Million) Table 9: Global - Biosimilar G-CSF Approved for Marketing Table 10: Global - Biosimilar G-CSF in Pipeline Table 11: Global - Patent Expiry Status of G-CSF Figure 18: Global - G-CSF Biosimilars Market Size by Value, 2014-2020E (US$ Millions) Table 12: Global - Biosimilar mAbs Approved for Marketing Table 13: Global - Biosimilar mAbs in Pipeline Figure 19: Global - mAb Biosimilars Market Size by Value, 2014-2020E (US$ Millions) Table 14: Global - Patent Expiry Status of mAbs Table 15: Global - Biosimilar Interferons Approved for Marketing Table 16: Global - Biosimilar Interferons in Pipeline Figure 20: Global - Interferon Biosimilars Market Size by Value, 2014-2020E (US$ Millions) Table 17: Global - Patent Expiry Status of Interferons Table 18: Biosimilar Development Pipeline in EU and the US Figure 21: Number of Biosimilars Approved in Europe, Japan and the US Table 19: Major Biological Patent Expiries in Europe, 2010-20 Figure 22: Europe Biosimilar Market Size by Value, 2014-20E (US$ Billions) Figure 23: Comparison of Innovator (Reference Products) and Biosimilar - ESA use in the EU27* (% of Treatment Days) Figure 24: Comparison of Innovator (Reference Products) and Biosimilar – G-CSFs use in the EU27* (% of Treatment Days) Figure 25: Biosimilar – Market Penetration in EU5 (% of treatment days) Figure 26: Biosimilar (HGH, EPO, G-CSF, INFLIXIMAB) Penetration of Accessible Markets in Europe Table 20: Biosimilar Drugs in Europe Figure 27: Europe Top Molecules Sales (MAT 12/2015), € Figure 28: Biosimilar Timeline in the US Figure 29: The US Biosimilars Market Size by Value, 2014-20E (US$ Millions) Table 21: Major Biological Patent Expiries in the US, 2010-20 Figure 30: Biosimilar Prorducts in Chinese Market Figure 31: China - Biosimilar Market Size by Value, 2014-20E (US$ Billions) Figure 32: Biosimilar Prorducts in Indian Market Figure 33: India - Biosimilar Market Size by Value, 2014-20E (US$ Millions) Figure 34: Global Biosimilars Pricing Analysis Figure 35: Global Biosimilars Market Attractiveness Index Figure 36: Number of Biosimilar Products in Registration, Pre-registration, and Phase III Figure 37: Global Biosimilars Sales at risk due to Patent Expiry, 2010-21 (US$ Bn) Figure 38: Patent Expiry of World’s Best Selling Biologics in the US and Europe Figure 39: Sales of Biologicals Going Off Patent Figure 40: Development Cost Comparison of Biosimilar, Biologic & Generic Figure 41: Global Biosimilars Market Share Competitors (2015) Table 22: Global Biosimilar Drugs Market Share by Manufacturer (2015) Figure 42: Sandoz Sales, FY2012-FY2016 (US$ Billions) Table 23: Sandoz - Biosimilars Approved for Marketing Table 24: Sandoz - Biosimilars in Pipeline Figure 43: Hospira Sales, FY2012-FY2016 (US$ Billions) Table 25: Hospira - Biosimilars Approved for Marketing Table 26: Hospira - Biosimilars in Pipeline Figure 44: TEVA Sales, FY2012-FY2016 (US$ Billions) Table 27: TEVA - Biosimilars Approved for Marketing Table 28: TEVA - Biosimilars in Pipeline Figure 45: Celltrion Sales, FY2012-FY2016 (US$ Billions) Table 29: Celltrion - Biosimilars Approved for Marketing Table 30: Celltrion - Biosimilars in Pipeline Figure 46: Biocad Sales, FY2012-FY2016 (US$ Billions) Table 31: Biocad - Biosimilars Approved for Marketing Table 32: Biocad - Biosimilars in Pipeline Figure 47: Dong-A Pharmaceutical Co., Ltd Sales, FY2012-FY2016 (US$ Billions) Table 33: Dong-A Pharmaceutical - Biosimilars Approved for Marketing Table 34: Dong-A Pharmaceutical - Biosimilars in Pipeline Figure 48: Stada Sales, FY2012-FY2016 (US$ Billions) Table 35: Dong-A Pharmaceutical - Biosimilars Approved for Marketing Table 36: Dong-A Pharmaceutical - Biosimilars in Pipeline

Sandoz, Hospira, TEVA, Celltrion, Biocad and Dong-A Pharmaceutical Co., Ltd.